Open Access Articles- Top Results for Ceftobiprole


Systematic (IUPAC) name
(6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-ylidene)- 2-nitroso-1-oxoethyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)- 3-pyrrolidinyl]-3-pyrrolidinylidene]methyl]-5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
AHFS/ International Drug Names
209467-52-7 7pxN
252188-71-9 (medocaril)
J01DI01 [1]
PubChem CID 6918430
ChemSpider 21106277 7pxY
UNII 5T97333YZK 7pxY
KEGG D08885 7pxY
ChEMBL CHEMBL520642 7pxN
Chemical data
Formula C20H22N8O6S2
534.568 g/mol
 14pxN (what is this?)  (verify)

Ceftobiprole (Zeftera/Zevtera) is a fifth-generation[2] cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, Pseudomonas aeruginosa, and enterococci.[3][4][5] It was discovered by Basilea Pharmaceutica[6] and was developed by Johnson & Johnson Pharmaceutical Research and Development.[7] It has been shown to be statistically noninferior to the combination of vancomycin and ceftazidime for the treatment of skin and soft tissue infections.[8]

It has been described as a fifth-generation cephalosporin,[9][10] though acceptance for this terminology is not universal.


Like other cephalosporins, ceftobiprole inhibits bacterial growth by blocking penicillin-binding protein, a key enzyme involved in cell wall synthesis. Ceftobiprole inhibits the 2a penicillin-binding protein (PBP) of methicillin-resistant Staphylococcus aureus and the 2x PBP of Streptococcus pneumoniae,[4] as well as the classic PBP-2 of MSSA. Ceftobiprole is resistant to staphylococcal β-lactamase.[6]

Mode of administration

Ceftobiprole is given intravenously; it cannot be given by mouth.

Regulatory approvals

Ceftobiprole has been approved for use in Canada, Switzerland, and the European Union.[11] It is under review by regulatory authorities in the United States, Australia, Russia, and South Africa.[12] In November 2008, the US FDA declined to approve ceftobiprole, citing data integrity concerns with two of the supporting studies,[13] and prompting Basilea to sue Johnson & Johnson for breach of license agreement on February 2009.[14]


  • RO0639141-000[6]
  • BAL9141[15]
  • Ceftobiprole medocaril


  1. ^ WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. Retrieved 2008-09-05. 
  2. ^ Kollef MH (December 2009). "New antimicrobial agents for methicillin-resistant Staphylococcus aureus". Crit Care Resusc 11 (4): 282–6. PMID 20001879. 
  3. ^ Yun HC, Ellis MW, Jorgensen JH (2007). "Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees". Diagnostic Microbiology and Infectious Disease 59 (4): 463–6. PMID 17911001. doi:10.1016/j.diagmicrobio.2007.06.023. 
  4. ^ a b Widmer A (2008). "Ceftobiprole: A new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus". Clin Infect Dis 46 (5): 656–8. PMID 18225983. doi:10.1086/526528. 
  5. ^ Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS (2008). "A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections". Clin Infect Dis 46 (5): 647–55. PMID 18225981. doi:10.1086/526527. 
  6. ^ a b c Hebeisen P, Heinze-Krauss I, Angehrn P et al. (2001). "In vitro and in vivo properties of Ro63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci". Antimicrob Agents Chemother 45 (3): 825–36. PMC 90381. PMID 11181368. doi:10.1128/AAC.45.3.825-836.2001. 
  7. ^
  8. ^ Noel, Gary J.; Karen Bush; Partha Bagchi; Juliana Ianus; Richard S. Strauss (2008). "A Randomized, Double-Blind Trial Comparing Ceftobiprole Medocaril with Vancomycin plus Ceftazidime for the Treatment of Patients with Complicated Skin and Skin-Structure Infections". Clin Infect Dis. 46 (5): 647-655. PMID 18225981. doi:10.1086/526527. 
  9. ^ Widmer AF (March 2008). "Ceftobiprole: a new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus". Clin. Infect. Dis. 46 (5): 656–8. PMID 18225983. doi:10.1086/526528. 
  10. ^ Kosinski MA, Joseph WS (July 2007). "Update on the treatment of diabetic foot infections". Clin Podiatr Med Surg 24 (3): 383–96, vii. PMID 17613382. doi:10.1016/j.cpm.2007.03.009. 
  11. ^ Basilea antibiotic to treat pneumonia wins European backing. Reuters, ZURICH | Wed Oct 23, 2013.
  12. ^ Basilea superbug drug approved in Canada, Reuters News, June 30, 2008
  13. ^
  14. ^ "Basilea Pharmaceutica Ltd. announces that the U.S. Food and Drug Administration (FDA) issued to the sponsor, Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (Johnson & Johnson PRD), a Complete Response Letter on ceftobiprole for the treatment of complicated skin and skin structure infections (cSSSI" (Press release). Basilea Pharmaceutica. 2009-07-02. Retrieved February 2, 2010. 
  15. ^ Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ (2002). "In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci". J Antimicrob Chemother 50 (6): 915–932. PMID 12461013. doi:10.1093/jac/dkf249.